1 / 10

Background

Background . Derma-Smoothe/FS ® (Fluocinolone acetonide ) Contains 0.01% fluocinolone acetonide in an oil base solution, Categorized as a low to medium potency corticosteroid preparation.

aurorette
Download Presentation

Background

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Background • Derma-Smoothe/FS® (Fluocinolone acetonide ) • Contains 0.01% fluocinolone acetonide in an oil base solution, • Categorized as a low to medium potency corticosteroid preparation. • Open-label safety studies were conducted to assess the adrenal (HPA axis) suppression potential of Derma-Smoothe/FS®, in children 2 to 12 years of age, with moderate to severe atopic dermatitis. • Derma-Smoothe/FS® is approved for pediatric use.

  2. Study Design • Multi-center, open-label safety studies for the treatment of atopic dermatitis (eczema) • Patient criteria: Moderate to severe atopic dermatitis involving greater than 50% of the total body surface area (BSA) • Dosage and duration of treatment: Twice daily application on diseased skin; continuous treatment for 4 weeks • Criteria for (Safety) evaluation: • Cosyntropin (ACTH) stimulation test • Serum Cortisol levels, baseline and post stimulation

  3. Study Design (cont.) • Day 1 prior to first treatment application, and at the end of 4 weeks treatment: • Pre-stimulation serum Cortisol level (baseline) • Immediately followed by stimulation with Cosyntropin test (intravenous) • Post-stimulation serum Cortisol level (after 60 minutes) • Data was compared using the paired t-test

  4. Treatment applications • ITT population 34 subjects • 18applied drug on> 75% BSA • 16 applied drug on 50-75% of BSA • Approximate drug used per day: 9.5 + 4.7 mL/day

  5. Solomon JR: Pediatric burns. Crit Care Clin 1:159-174, 1985

  6. Cortisol Levels Prior to Treatment Cortisol levels Prior to treatment No. of patients (N=34) ACTH stimulation test criterion for normal response at 60 minutes: approximate doubling of the basal plasma cortisol value.

  7. Cortisol levels after 4 weeks of Treatment Cortisol levels end of 4 weeks Treatment. No. of patients (N=34) ACTH stimulation test criterion for normal response at 60 minutes: approximate doubling of the basal plasma cortisol value.

  8. Example of drug exposure estimation 4 fl oz. bottle of Derma-Smoothe/FS® contains 12mg of fluocinolone acetonide (FA) • Ave. daily dose of 9.5mL of Derma-Smoothe/FS® ~ 1mg of FA • Note: 1-2% corticosteroid is absorbed topically. • Based on a 1-2% absorption, the total FA absorbed is 0.02mg/day Reference: (H.I Maibach, Ch. Surber, Topical Corticosteroids, 1992; 165, 199, 201 Comparative quantitative studies utilized in the FDA diseased-skin protocol demonstrate that as little as 14 g/week of clobetasol propionate may induce suppression, and over 49 g/week of betamethasone dipropionate is required to significantly reduce plasma cortisol levels.

  9. Conclusion • Four weeks twice daily application of Derma-Smoothe/FS® (fluocinolone acetonide 0.01%) to diseased skin involving over 50 to 90% of body surface area -- Nochange in morning baseline value of plasma Cortisol, nor did it affect Cortisol stimulation by administration of ACTH.

  10. Efficacy Efficacy results after 4 weeks treatment showed excellent or better (75% to 100%) improvement in more than 60% of the subjects.

More Related